NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55289-0903-12 | 55289-0903 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 31, 2009 | In Use | |
63323-0192-02 | 63323-0192 | Fludarabine Phosphate | Fludarabine | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov 16, 2007 | In Use | |
00006-0464-05 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Mar 26, 2003 | Dec 31, 2020 | In Use |
00085-3004-03 | 00085-3004 | Temozolomide | Temodar | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
45963-0733-60 | 45963-0733 | Doxorubicin Hydrochloride | Doxorubicin hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Nov 1, 2014 | In Use | |
00143-9290-01 | 00143-9290 | Estradiol Valerate | Estradiol Valerate | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Apr 21, 2020 | In Use | ||
23155-0240-42 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan 3, 2014 | In Use | |
50242-0917-86 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Aug 11, 2016 | In Use | |
65162-0057-33 | 65162-0057 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan 20, 2016 | In Use | ||
00143-1254-01 | 00143-1254 | Hydrocortisone | Hydrocortisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 18, 1973 | Apr 30, 2017 | In Use |
71288-0108-06 | 71288-0108 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Jun 26, 2020 | In Use | |
70518-3046-00 | 70518-3046 | Raloxifene | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Mar 11, 2021 | In Use | ||
00006-4119-02 | 00006-4119 | Human Papillomavirus 9-valent Vaccine, Recombinant | GARDASIL 9 | 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Dec 10, 2014 | May 22, 2019 | In Use |
16714-0248-01 | 16714-0248 | Fosaprepitant dimeglumine | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jan 28, 2023 | In Use | |
50090-1658-01 | 50090-1658 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 23, 2015 | In Use | |
63187-0266-20 | 63187-0266 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 1, 2017 | In Use | |
70710-1791-01 | 70710-1791 | Dexamethasone | Dexamethasone | 0.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 18, 2024 | In Use | |
61919-0565-30 | 61919-0565 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 22, 2019 | In Use | |
33261-0417-15 | 33261-0417 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
53217-0300-06 | 53217-0300 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
50090-7480-02 | 50090-7480 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 20, 2024 | In Use | ||
70625-0311-01 | 70625-0311 | FOSAPREPITANT | FOSAPREPITANT | 150.0 mg/mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov 3, 2021 | In Use | |
70121-2537-06 | 70121-2537 | Leuprolide acetate | Leuprolide acetate | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov 7, 2022 | In Use | |||
00574-0870-05 | 00574-0870 | Estradiol Valerate | Estradiol Valerate | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Mar 31, 2010 | In Use | ||
43063-0273-04 | 43063-0273 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 27, 2011 | In Use |
Found 11765 results — Export these results